Lastest Stories by Trey Thoelcke

Here is an assessment of how safe the dividend at Lowe's appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Apple's dividend may be small but it is regular. Here is an assessment of how safe its payout appears to be based on a variety of metrics.
Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe the dividend at Abbott Laboratories appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe PepsiCo's dividend appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe Walmart's dividend appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Here is an assessment of how safe the dividend at Walgreens appears to be after last year's cut, based on a variety of metrics.
Here is an assessment of how safe Altria’s generous dividend appears to be based on a variety of metrics.
Here is an assessment of how safe Exxon Mobil’s dividend appears to be based on a variety of metrics.
Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.
Here is an assessment of how safe IBM’s dividend appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
As the year got underway, biotechs were in focus among the notable insider buying, especially in two companies focused on treatments for the eye.
Here is an assessment of how safe Procter & Gamble’s dividend appears to be based on a variety of metrics.
Here is an assessment of how safe Ford’s dividend appears to be based on a variety of metrics.